Viral vaccine trains body to fight advanced cancers

NCT ID NCT01147965

Summary

This early-stage study tested a new cancer vaccine designed to teach the body's immune system to recognize and attack tumors. It involved 43 people with advanced colorectal, lung, breast, or prostate cancer that had stopped responding to standard treatments. The main goals were to check the vaccine's safety and see if it triggered a strong immune response against the cancer.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Duke Cancer Research Institute, Duke University

    Durham, North Carolina, 27710, United States

  • Medical Oncology Associates, PS

    Spokane, Washington, 99208, United States

Conditions

Explore the condition pages connected to this study.